AI-powered comprehensive assessment for coronary artery disease.
Category: Specialized. Pricing: priced per the vendor's website. Last modified: 2026-09-11.
Cleerly is a web-based, AI-driven platform that quantifies atherosclerosis by measuring plaque volume, composition, length, and location. The software evaluates stenosis severity in 2D and 3D, providing clinically actionable insights to support cardiac care assessment and therapeutic decision-making. It integrates with existing clinical workflows to assist providers in characterizing plaque and detecting ischemia.
Not editorially tested: One AI Guide has not published a complete hands-on test record for this tool.
Published by LUMIVEX for One AI Guide.
Editorial lead: Said El Moussaoui. Our methodology is published at /how-we-rate.
Official vendor website: see the vendor link below.
Cleerly is a specialized tool. AI-powered comprehensive assessment for coronary artery disease.
The One AI Guide catalog currently records Cleerly as priced per the vendor's website. This is a directory summary, not a current vendor quote; always check the vendor's site for the latest plans before signing up.
The catalog does not currently record Cleerly as Free or Freemium. That is not proof that no trial or limited offer exists; check the vendor's site for current options.
Common use cases include Analyzing CCTA scans for CAD risk assessment, Conducting serial CCTA comparisons to track plaque progression, and Guiding therapeutic decision-making for heart disease patients.
The One AI Guide catalog currently highlights these strengths: Provides granular analysis of plaque volume, phenotype, and stenosis severity; Features clinical validation through trials like CREDENCE and PACIFIC; Integrates with clinical tools like PowerScribe to streamline reporting workflows.